Celcuity Management
Management Kriterienprüfungen 2/4
Celcuity CEO ist Brian Sullivan , ernannt in Jan 2012, hat eine Amtszeit von 14.58 Jahren. Die jährliche Gesamtvergütung beträgt $16.37M , bestehend aus 3.5% Gehalt und 96.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.38% der Aktien des Unternehmens, im Wert von $292.28M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.6 Jahre bzw. 11 Jahre.
Wichtige Informationen
Brian Sullivan
Geschäftsführender
US$16.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 3.52% |
| Amtszeit als Geschäftsführer | 14.6yrs |
| Eigentum des Geschäftsführers | 6.4% |
| Durchschnittliche Amtszeit des Managements | 5.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 11yrs |
Jüngste Management Updates
Recent updates
CELC: FDA Breast Cancer Approval Will Drive Commercial Launch Reappraisal
Celcuity's analyst price target has been adjusted from $165 to $178 as analysts factor in the recent Revtorpyk FDA approval, cleaner safety profile, and premium pricing potential into their updated launch and revenue assumptions. Analyst Commentary Recent research on Celcuity highlights how the Revtorpyk approval and updated clinical data are feeding into higher valuation frameworks, even as some analysts refine their models around study outcomes and safety profiles.
CELC: VIKTORIA-1 Data And Priority Review Will Drive Future Repricing
The updated analyst price target for Celcuity shifts to $145 from $94, reflecting how analysts are balancing recent VIKTORIA-1 efficacy and safety data with views on gedatolisib's competitive position and potential launch opportunities. Analyst Commentary Recent Street research on Celcuity reflects a mix of optimism about gedatolisib's potential and a more careful stance on execution risk following new VIKTORIA-1 data.
CELC: VIKTORIA Breast Cancer Data Will Drive Future Upside Potential
Celcuity's analyst price target has been raised from $116.70 to about $161.09, with analysts citing updated views on gedatolisib's efficacy, competitive positioning, and upcoming study readouts as key drivers behind the revision. Analyst Commentary Recent Street research on Celcuity shows a mix of optimism about gedatolisib's commercial prospects and caution around safety, competitive threats, and clinical nuances from the VIKTORIA-1 program.Priority FDA Review And Phase III Data Will Transform This Oncology Pure Play
Catalysts About Celcuity Celcuity is a clinical stage oncology company focused on developing gedatolisib, a targeted therapy for advanced breast and prostate cancers. What are the underlying business or industry changes driving this perspective?Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
Summary Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones. I maintain a long-term Buy rating on CELC, anticipating further upside as pivotal data, regulatory filings, and potential M&A activity unfold through 2027–2028. Read the full article on Seeking AlphaIs Celcuity (NASDAQ:CELC) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Summary Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in combination therapies for advanced breast cancer, with significant ORR and mPFS improvements. Financially, Celcuity has a strong cash position and secured funding, ensuring a runway through 2026, despite patent expiration risks. Despite Stifel's buy rating and blockbuster potential, the risk-reward profile of CELC remains unattractive at this stage. Read the full article on Seeking AlphaIs Celcuity (NASDAQ:CELC) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Summary Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks. Read the full article on Seeking AlphaDoes Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$226m |
| Mar 31 2026 | n/a | n/a | -US$193m |
| Dec 31 2025 | US$16m | US$577k | -US$177m |
| Sep 30 2025 | n/a | n/a | -US$163m |
| Jun 30 2025 | n/a | n/a | -US$149m |
| Mar 31 2025 | n/a | n/a | -US$127m |
| Dec 31 2024 | US$7m | US$525k | -US$112m |
| Sep 30 2024 | n/a | n/a | -US$94m |
| Jun 30 2024 | n/a | n/a | -US$83m |
| Mar 31 2024 | n/a | n/a | -US$73m |
| Dec 31 2023 | US$2m | US$210k | -US$64m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$2m | US$106k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$1m | US$260k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$469k | US$250k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$992k | US$250k | -US$7m |
Vergütung im Vergleich zum Markt: BrianDie Gesamtvergütung ($USD16.37M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.93M).
Entschädigung vs. Einkommen: BrianDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Brian Sullivan (64 yo)
Mr. Brian F. Sullivan is the Co-Founder of Celcuity Inc. and has been its Chairman and Chief Executive Officer since 2012 and served as its Chief Financial Officer. Mr. Sullivan Co-founded Entegris, Inc. i...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder | 14.6yrs | US$16.37m | 6.38% $ 292.3m | |
| Co-Founder | 14.6yrs | US$4.19m | 2.56% $ 117.2m | |
| Chief Financial Officer | 9.1yrs | US$3.41m | 0.040% $ 1.9m | |
| Head of Investor Relations & Corporate Communications | no data | keine Daten | keine Daten | |
| General Counsel | 1.8yrs | keine Daten | keine Daten | |
| Acting Head of Clinical Operations | 5.6yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 4.4yrs | keine Daten | keine Daten | |
| Chief Commercial Officer | 2.5yrs | keine Daten | keine Daten |
Erfahrenes Management: Das Managementteam von CELC ist erfahren und erfahren (durchschnittliche Amtszeit von 5.6 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder | 14.6yrs | US$16.37m | 6.38% $ 292.3m | |
| Co-Founder | 14.6yrs | US$4.19m | 2.56% $ 117.2m | |
| Independent Director | 9.6yrs | US$140.00k | 0.16% $ 7.4m | |
| Independent Director | 12.5yrs | US$140.00k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$140.00k | 0.022% $ 1.0m | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 7.6yrs | keine Daten | keine Daten |
Erfahrener Vorstand: CELCDie Vorstandsmitglieder sind sehr erfahren ( 11 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 22:20 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Celcuity Inc. wird von 17 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |